journal article·2014-02

Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin

Jasmeet S. Khara, Ying Wang, Xi-Yu Ke, Shaoqiong Liu, Sandra M. Newton, Paul R. Langford, Yi Yan Yang, Pui Lai Rachel Ee

Biomaterials· Volume 35· Issue 6
Publisher page

Abstract

The rapid emergence of multi-drug resistant tuberculosis (TB) and the lack of effective therapies have prompted the development of compounds with novel mechanisms of action to tackle this growing public health concern. In this study, a series of synthetic cationic α-helical antimicrobial peptides (AMPs) modified with different hydrophobic amino acids was investigated for their anti-mycobacterial activity, both alone and in synergistic combinations with the frontline anti-tuberculosis drug rifampicin. The addition of thiol groups by incorporating cysteine residues in the AMPs did not improve anti-mycobacterial activity against drug-susceptible and drug-resistant Mycobacterium tuberculosis, while the enhancement of peptide hydrophobicity by adding methionine residues increased the efficacy of the primary peptide against all strains tested, including clinically isolated multidrug-resistant mycobacteria. The peptide with the optimal composition M(LLKK)2M was bactericidal, and eradicated mycobacteria via a membrane-lytic mechanism as demonstrated by confocal microscopic studies. Mycobacteria did not develop resistance after multiple exposures to sub-lethal doses of the peptide. In addition, the peptide displayed synergism with rifampicin against both Mycobacterium smegmatis and Mycobacterium bovis BCG and additivity against M. tuberculosis. Moreover, such combination therapy is effective in delaying the emergence of rifampicin resistance. The ability to potentiate anti-TB drug activity, kill drug-resistant bacteria and prevent drug resistance highlights the potential utility of the peptide in combating multidrug-resistant TB.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Immune Response and Inflammation · Chemical Synthesis and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (40)

Show source-provided references
1. WHO · 2012
2. WHO · 2010
3. Rising to the challenge: new therapies for tuberculosis10.1016/j.tim.2013.05.002 ↗
4. Antimicrobial peptides stage a comeback10.1038/nbt.2572 ↗
5. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies10.1038/nbt1267 ↗
6. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes
7. Crystallization of antimicrobial pores in membranes: magainin and protegrin10.1016/S0006-3495(00)76448-4 ↗
8. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α-helical antimicrobial and cell non-selective membrane-lytic peptides10.1016/S0005-2736(99)00200-X ↗
9. Antimicrobial peptides of multicellular organisms10.1038/415389a ↗
10. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis10.1016/j.peptides.2004.04.003 ↗
11. Anti-tuberculosis activity of α-helical antimicrobial peptides: de novo designed L-and D-Enantiomers versus L-and D-LL3710.2174/092986611794578288 ↗
12. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils10.1128/IAI.70.8.4591-4599.2002 ↗
13. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis10.1093/jac/47.5.575 ↗
14. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis10.1128/iai.64.3.926-932.1996 ↗
15. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study10.1034/j.1399-3003.2000.16a20.x ↗
16. Arming the enemy: the evolution of resistance to self-proteins10.1099/mic.0.26265-0 ↗
17. A linguistic model for the rational design of antimicrobial peptides10.1038/nature05233 ↗
18. Synthetic cationic amphiphilic α-helical peptides as antimicrobial agents10.1016/j.biomaterials.2010.11.054 ↗
19. The effect of thiol functional group incorporation into cationic helical peptides on antimicrobial activities and spectra10.1016/j.biomaterials.2011.08.020 ↗
20. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides10.1128/AAC.00175-13 ↗
21. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis10.1016/j.ijantimicag.2012.09.015 ↗
22. Assessment of immunity to mycobacterial infection with luciferase reporter constructs10.1128/IAI.67.9.4586-4593.1999 ↗
23. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent10.1038/nnano.2009.153 ↗
24. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis10.1016/j.biomaterials.2009.12.042 ↗
25. Reproducibility of the microdilution checkerboard method for antibiotic synergy10.1128/AAC.37.3.613 ↗
26. Jacobs · 2001
27. Eliopoulos · 1991
28. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes10.1021/bi960835f ↗
29. Design of novel analogue peptides with potent antibiotic activity based on the antimicrobial peptide, HP (2-20), derived from N-terminus of Helicobacter pylori ribosomal protein L110.1016/S0167-4838(02)00373-4 ↗
30. Stabilized helical peptides: overview of the technologies and therapeutic promises10.1517/17460441.2011.603723 ↗
31. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index10.1074/jbc.M413406200 ↗
32. Role of peptide hydrophobicity in the mechanism of action of a-helical antimicrobial peptides10.1128/AAC.00925-06 ↗
33. Role of positional hydrophobicity in the leishmanicidal activity of magainin 210.1128/AAC.48.8.2980-2986.2004 ↗
34. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update10.1054/tuld.1998.0002 ↗
35. NCCLS · 1999
36. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity10.1128/AAC.48.8.3112-3118.2004 ↗
37. In vitro bactericidal activity of human β-defensin 3 against multidrug-resistant nosocomial strains10.1128/AAC.50.2.806-809.2006 ↗
38. Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides10.1128/AAC.01231-09 ↗
39. Protective effects of the combination of α-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection10.1093/jac/dkn393 ↗
40. Structure-function relationships of temporins, small antimicrobial peptides from amphibian skin10.1046/j.1432-1327.2000.01143.x ↗